Compare Stocks → Strange new buyer driving up gold (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:CRYNASDAQ:CSIINYSE:LGVNASDAQ:SGHTNASDAQ:SIBN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRYCryoLife$19.05$16.95▼$32.34$703.22M1.53198,221 shs7,792 shsCSIICardiovascular Systems$20.00$19.98$12.26▼$20.57$843.96M0.74765,906 shs4,300 shsLGVLongview Acquisition Corp. II$10.09$10.09$9.68▼$10.15N/AN/AN/AN/ASGHTSight Sciences$5.13-2.1%$4.84$1.04▼$11.20$254.19M2.83223,623 shs69,117 shsSIBNSI-BONE$15.22-0.5%$17.31$14.84▼$29.51$624.93M1.2436,689 shs448,329 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRYCryoLife0.00%0.00%0.00%0.00%0.00%CSIICardiovascular Systems0.00%0.00%0.00%0.00%+0.15%LGVLongview Acquisition Corp. II0.00%0.00%0.00%0.00%0.00%SGHTSight Sciences-2.60%-14.10%+2.95%+1.75%-47.02%SIBNSI-BONE+0.46%-2.49%-5.26%-17.48%-29.56%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRYCryoLifeN/AN/AN/AN/AN/AN/AN/AN/ACSIICardiovascular SystemsN/AN/AN/AN/AN/AN/AN/AN/ALGVLongview Acquisition Corp. IIN/AN/AN/AN/AN/AN/AN/AN/ASGHTSight Sciences0.8059 of 5 stars1.04.00.00.02.53.30.6SIBNSI-BONE4.2317 of 5 stars4.52.00.03.31.72.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRYCryoLifeN/AN/AN/AN/ACSIICardiovascular SystemsN/AN/AN/AN/ALGVLongview Acquisition Corp. IIN/AN/AN/AN/ASGHTSight Sciences2.00Hold$4.60-10.33% DownsideSIBNSI-BONE3.00Buy$26.6775.21% UpsideCurrent Analyst RatingsLatest CRY, SGHT, SIBN, CSII, and LGV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/3/2024SIBNSI-BONENeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.003/28/2024SIBNSI-BONEPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.002/27/2024SIBNSI-BONEMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $26.002/27/2024SIBNSI-BONECantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.002/27/2024SIBNSI-BONETruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $24.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRYCryoLife$253.23M0.00N/A23.30$8.46 per share0.00CSIICardiovascular Systems$239.84M3.52N/AN/A$6.12 per share3.27LGVLongview Acquisition Corp. IIN/AN/AN/AN/AN/AN/ASGHTSight Sciences$81.06M3.14N/AN/A$2.47 per share2.08SIBNSI-BONE$138.89M4.50N/AN/A$4.18 per share3.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRYCryoLife-$16.68M$0.03596.200.00N/A0.63%4.24%1.63%N/ACSIICardiovascular Systems-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/ALGVLongview Acquisition Corp. II$7.40MN/A0.00∞N/AN/AN/AN/AN/ASGHTSight Sciences-$55.55M-$1.14N/AN/AN/A-68.53%-41.94%-30.64%5/2/2024 (Confirmed)SIBNSI-BONE-$43.34M-$1.14N/AN/AN/A-31.20%-28.22%-20.53%5/6/2024 (Confirmed)Latest CRY, SGHT, SIBN, CSII, and LGV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2024N/ASIBNSI-BONE-$0.29N/A+$0.29N/AN/AN/A 5/2/2024N/ASGHTSight Sciences-$0.29N/A+$0.29N/AN/AN/A 3/7/2024Q4 2023SGHTSight Sciences-$0.35-$0.22+$0.13-$0.22$18.70 million$18.75 million 2/26/2024Q4 2023SIBNSI-BONE-$0.29-$0.27+$0.02-$0.27$38.60 million$38.86 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRYCryoLifeN/AN/AN/AN/AN/ACSIICardiovascular SystemsN/AN/AN/AN/AN/ALGVLongview Acquisition Corp. IIN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ASIBNSI-BONEN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRYCryoLife0.994.212.93CSIICardiovascular Systems0.086.044.92LGVLongview Acquisition Corp. IIN/AN/AN/ASGHTSight Sciences0.2613.2912.65SIBNSI-BONE0.219.018.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRYCryoLife81.57%CSIICardiovascular Systems86.61%LGVLongview Acquisition Corp. IIN/ASGHTSight Sciences55.51%SIBNSI-BONE98.11%Insider OwnershipCompanyInsider OwnershipCRYCryoLife4.50%CSIICardiovascular Systems3.80%LGVLongview Acquisition Corp. II26.35%SGHTSight Sciences27.10%SIBNSI-BONE5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRYCryoLife1,20039.33 million37.56 millionOptionableCSIICardiovascular Systems78042.20 million40.59 millionOptionableLGVLongview Acquisition Corp. II3N/AN/ANot OptionableSGHTSight Sciences21449.55 million36.12 millionOptionableSIBNSI-BONE34441.06 million38.85 millionOptionableCRY, SGHT, SIBN, CSII, and LGV HeadlinesSourceHeadlineSI-BONE (NASDAQ:SIBN) Reaches New 1-Year Low at $14.84americanbankingnews.com - April 17 at 5:44 AMAllspring Global Investments Holdings LLC Cuts Holdings in SI-BONE, Inc. (NASDAQ:SIBN)marketbeat.com - April 17 at 5:01 AMSI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024globenewswire.com - April 15 at 4:09 PMSI-BONE (NASDAQ:SIBN) Sets New 52-Week Low at $14.84marketbeat.com - April 15 at 10:57 AMSI-BONE (NASDAQ:SIBN) Shares Up 4.6%marketbeat.com - April 9 at 1:50 PMSI-BONE, Inc. (NASDAQ:SIBN) Stock Position Lifted by Vanguard Group Inc.marketbeat.com - April 9 at 4:08 AMKent Lake Capital LLC Has $8.40 Million Stake in SI-BONE, Inc. (NASDAQ:SIBN)marketbeat.com - April 6 at 7:28 PMInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,425 Shares of Stockinsidertrades.com - April 5 at 7:46 AMSI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $37,466.25 in Stockmarketbeat.com - April 4 at 9:43 PMSI-Bone’s Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth Prospectsmarkets.businessinsider.com - April 3 at 10:32 PMSI-BONE (NASDAQ:SIBN) Receives "Buy" Rating from Needham & Company LLCmarketbeat.com - April 3 at 12:14 PMAssenagon Asset Management S.A. Acquires 201,615 Shares of SI-BONE, Inc. (NASDAQ:SIBN)marketbeat.com - March 30 at 4:51 AMPeeling Back The Layers: Exploring SI-BONE Through Analyst Insightsmarkets.businessinsider.com - March 28 at 7:19 PMSI-BONE (NASDAQ:SIBN) Research Coverage Started at Piper Sandlermarketbeat.com - March 28 at 8:28 AMSI-BONE (NASDAQ:SIBN) Reaches New 52-Week Low at $15.47marketbeat.com - March 22 at 11:08 AMInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Director Sells 2,500 Shares of Stockinsidertrades.com - March 15 at 11:59 AMSI-BONE, Inc. (NASDAQ:SIBN) Insider Sells $56,010.60 in Stockinsidertrades.com - March 15 at 11:42 AMBuy Rating Affirmed for SI-Bone on Expansion and Market Growth Strategiesmarkets.businessinsider.com - March 13 at 4:07 PMSIBN Apr 2024 2.500 putfinance.yahoo.com - March 10 at 7:08 PMSIBN Jul 2024 10.000 putfinance.yahoo.com - March 10 at 7:08 PMSI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024globenewswire.com - March 4 at 4:09 PMWhen Will SI-BONE, Inc. (NASDAQ:SIBN) Become Profitable?finance.yahoo.com - February 28 at 8:48 AMSI-BONE Shares Drop 14% Following 4Q Lossmarketwatch.com - February 27 at 2:57 PMBeyond The Numbers: 4 Analysts Discuss SI-BONE Stockmarkets.businessinsider.com - February 27 at 2:57 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeBitcoin Sells Off, Bringing New Spot ETFs Along With ItMarch 22, 2024 7:00 AMView Bitcoin Sells Off, Bringing New Spot ETFs Along With ItChecking in with 5 Bitcoin Stocks Ahead of Bitcoin's HalvingApril 17, 2024 7:10 AMView Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's HalvingAll Headlines Company DescriptionsCryoLifeNYSE:CRYCryoLife, Inc. engages in the manufacture, process and distribution of medical devices and implantable human tissues. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue products, aortic stents and stent grafts, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment focuses on revenues from preservation of cardiac and vascular implantable human tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.Cardiovascular SystemsNASDAQ:CSIICardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.Longview Acquisition Corp. IINYSE:LGVLongview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.Sight SciencesNASDAQ:SGHTSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.SI-BONENASDAQ:SIBNSI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.